In a breakthrough for the treatment of those with advanced kidney cancer, the FDA approved two immunotherapy drugs, nivolumab and ipilimumab, to be provided in combination as a first line treatment option. You can read more here. The FDA granted these applications priority review and breakthrough therapy designation. This is an exciting development for the community as there were a significant number of patients in the trials who experienced very favorable responses in terms of tumor shrinkage.
The FDA official announcement is here.